3-(3-Hydroxy-Phenethyl)-5-Phenethyl-4,5-Dihydro-Isoxazole (Enantiomeric Mix)

3-(3-Hydroxy-Phenethyl)-5-Phenethyl-4,5-Dihydro-Isoxazole (Enantiomeric Mix)

SCHEMBL2912741

Oc1cccc(CCC2=NOC(CCc3ccccc3)C2)c1

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 12/20 0.45
OPRM1 P35372 11/20 0.45
OPRD1 P41143 9/20 0.45
DRD2 P14416 3/20 0.43
DRD3 P35462 3/20 0.43
PPARG P37231 2/20 0.42
PPARA Q07869 2/20 0.42
CALM1 P0DP23 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2922253 0.88 OPRM1 (0.46) OPRK1OPRM1OPRD1
3-(4-Hydroxy-Phenethyl)-5-Phenethyl-4,5-Dihydro-Isoxazole (Enantiomeric Mix) SCHEMBL2923098 0.88 DRD2 (0.47) OPRK1OPRM1OPRD1DRD2DRD3
SCHEMBL2923312 0.88 SLC6A2 (0.45) PPARGPPARA
3-(2-Hydroxy-Phenethyl)-5-Phenethyl-4,5-Dihydro-Isoxazole (Enantiomeric Mix) SCHEMBL2920016 0.81 DRD1 (0.39) PPARGPPARA
SCHEMBL2920823 0.78 SLC6A2 (0.44) PPARGPPARA
SCHEMBL2913753 0.77
SCHEMBL2916369 0.77
SCHEMBL28145201 0.76 SLC6A2 (0.43) PPARGPPARA
SCHEMBL2923116 0.74 PPARG (0.40) PPARGPPARA
3-Phenethylphenol SCHEMBL717571 0.73 OPRK1 (0.74) OPRK1OPRM1OPRD1DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267784-A1 NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA 2010-10-21 US disclosed
US-20100267784-A1 NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA 2010-10-21 US disclosed
US-20100267784-A1 NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA 2010-10-21 US disclosed
EP-2222653-A1 NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY Pulkkinen, Juha (FI) 2010-09-01 EP disclosed
WO-2009066009-A1 NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA (FI) 2009-05-28 WO disclosed
WO-2009066009-A1 NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA (FI) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267784-A1 NOVEL 4,5-DIHYDROISOXAZOLES WITH ESTROGENIC ACTIVITY ESR2, GPER1, CYP19A1 OPRK1 367/4885OPRM1 524/4885OPRD1 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.